Skip to content

EBIT at other companies

Gilead Sciences logo
Gilead SciencesGILD
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
Arrowhead Research logo
Arrowhead ResearchARWR
LQD
Liquidia CorporationLQDA
Alkermes logo
AlkermesALKS
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s EBIT?
Mirum Pharmaceuticals, Inc. (MIRM) reported EBIT of -$789.47M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s EBIT changed year-over-year?
Mirum Pharmaceuticals, Inc.'s EBIT decreased by 5099.7% year-over-year, from -$15.18M to -$789.47M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s EBIT?
Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s EBIT has grown at a -40.2% compound annual growth rate (CAGR), from -$173.41M to -$22.14M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.